Home > Dermatology > EADV 2019 > Urticaria > Ligelizumab for CSU: symptom control and high response rates in re-treatment

Ligelizumab for CSU: symptom control and high response rates in re-treatment

Presented By
Prof. Marcus Maurer, Charité – Universitätsmedizin Berlin, Germany
Conference
EADV 2019
Depending on the dosing, ligelizumab has displayed more symptom control in chronic spontaneous urticaria [CSU] than omalizumab. In case of re-occurrence of active CSU after stop of therapy, response rates with ligelizumab re-treatment were very encouraging. Chronic urticaria is a common, mast cell-driven disease with an increasing world-wide incidence [1]. Ligelizumab, a monoclonal anti-IgE antibody that prevents the cascade of allergic reaction by inhibiting the binding of free IgE to mast cells and basophils has higher affinity to IgE than omalizumab [2,3]. A recently published core 2b randomised controlled trial with 382 adult CSU patients, compared response rates of CSU to ligelizumab at different doses to omalizumab and placebo [1]. One of the questions that Prof. Marcus Maurer and colleagues set out to answer was how long after a withdrawal of ligelizumab the patients with complete response would experience a loss of efficacy [4]. Attaining co...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on